Prolactin response to bromocriptine in flunarizine-treated migrainous women

Clinical Neuropharmacology

Volumn 20, Issue 3, 1997, Pages 234-238

  Cupini, L M ^a,d   Calabresi, P ^a   Silvestrini, M ^a   Troisi, E ^c   Matteis, M ^c   Argiro G ^b   Bernardi, G ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b S EUGENIO HOSPITAL   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Dopaminergic system; Flunarizine; Migraine

Indexed keywords

BROMOCRIPTINE; CALCIUM CHANNEL; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ESTRADIOL; FLUNARIZINE; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; PROGESTERONE; PROLACTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MIGRAINE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE;

EID: 0030952748     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199706000-00007     Document Type: Article

References (15)

1. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 1981;21:235-9.
2. Amery WK, Cers LI, Aerts TJL. Flunarizine a calcium entry blocker in migraine prophilaxis. Headache 1985;5:249-54.
3. Rascol A, Montastruc JL, Rasco O. Flunarizine versus pizotifene: a double-blind study in the prophylaxis of migraine. Headache 1986;26:83-5.
4. Ambrosio C, Stefanini E. Interaction of flunarizine with dopamine D2 and D1 receptors. Eur J Pharmacol 1991;197:221-3.
5. Wober C, Brucke T, Wober-Bingol C, et al. Dopamine D2 receptor blockade and antimigraine action of flunarizine. Cephalalgia 1994;14-235-40.
6. Brucke T, Wober CH, Podreka I, Wober-Bingol C, et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapiramidal side effects. A SPECT study. J Cereb Blood Flow Metab 1995;15:513-8.
7. Diana M, Pani L, Rossetti Z, et al. Flunarizine attenuates cocaine-induced inhibition of A9 dopaminergic neurons. Pharmacol Res 1991;24:197-203.
8. Devoto P, Pani L, Kuzmin A, De Montis G. Inhibition of [3H]dopamine uptake by flunarizine. Eur J Pharmacol 1991;203:67-9.
9. Maestri E, Manzoni GC, Marchesi G, et al. Effect of flunarizine on pituitary secretion by healthy men and in women with migraine. Eur J Clin Pharmacol 1987;32:525-7.
10. Bonuccelli U, Piccini P, Paoletti AM, et al. Flunarizine increases PRL secretion in normal and in migraineous women. J Neural Transm 1988;74:45-53.
11. Cortelli P, Santucci M, Righetti F, et al. Neuroendocrinological evidence of an anti-dopaminergic effect of flunarizine. Acta Neurol Scand 1988;77:289-92.
12. Cerbo R, Formisano P, Falaschi P, et al. Anterior pituitary hormone secretion during treatment with flunarizine in migrainous patients. Clin Neuropharmacol 1988;3:263-7.
13. Piccini P, Nuti A, Paoletti AM, et al. Possible involvement of dopaminergic mechanisms in the antimigraine action of flunarizine. Cephalalgia 1990;10:3-8.
14. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988;8:10-73.
15. Martin JB, Reichlin S. Clinical neuroendocrinology. Philadelphia: F. A. Davis, 1987.